MAY 12, 2021 9:30 PM PDT

Medical Cannabis Increases Quality of Life By Over 50 Percent: UK Study

WRITTEN BY: Angela Dowden

Real world data from a British study involving over 900 medical cannabis patients has found high quality evidence (using the EQ-5D-5L rating of quality of life) that medicinal cannabis has a big impact on a patient's ability to lead a more normal life.

The patients involved were part of Project Twenty21, which was setup by the scientific body Drug Science. Project Twenty21 patients were supplied with subsidized medicinal cannabis on the agreement that Drug Science could collect and analyse their data. The overarching aim of the project is to collect data that may in future persuade the UK’s National Health Service to fund cannabis medicine where the benefits of treatment are proven to outweigh the potential risks.

The results have been very impressive, with a 51 percent increase in patients’ self-reported health and ability to lead a more normal life after 3 months.

Using EQ-5D-5L lends authority and standardisation to the data collected — this system of  collecting quality of life data uses five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels ranging from no problems to extreme problems and the patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. Ultimately the boxes ticked can be combined into a 5-digit number that describes the patient’s health state.

The data confirmed that the medicinal cannabis patients were in substantially poorer health than the general population going into the trial, and had been unable to manage their diagnosed conditions with commonly prescribed medications.

This is the first published real-world data to be collected on medical cannabis in the United Kingdom. As well as the 51 percent increase in self-reported physical health, patients reported significant improvements in their ability to manage debilitating secondary conditions such as anxiety, insomnia and depression. Almost two-thirds of patients in the study also reported they had previously felt compelled to turn to illegal use in an attempt to manage their conditions.

Responding to the study, Prof David Nutt, Founder of Drug Science said “A lack of clinical evidence has made it difficult for doctors to confidently prescribe legal medical cannabis in the UK. These new findings provide a major step forward, and help to clarify the benefit these medicines can have for thousands of seriously ill patients.”

Sources: Leafie, Drug Science

About the Author
  • I'm a journalist and author with many year's experience of writing for both a consumer and professional audience, mostly on nutrition, health and medical prescribing. My background is food science and I'm a registered nutritionist.
You May Also Like
MAY 24, 2021
Health & Medicine
How do healthcare insurance disruptions affect access and affordability to care?
MAY 24, 2021
How do healthcare insurance disruptions affect access and affordability to care?
Have you ever been in between health insurance coverage and pushed off receiving healthcare that you needed? According t ...
JUN 01, 2021
Neuroscience
Depression Linked to Rapid Decline in Kidney Function
JUN 01, 2021
Depression Linked to Rapid Decline in Kidney Function
Researchers have known for some time that depressive symptoms are linked to rapid kidney function decline among patients ...
JUN 08, 2021
Immunology
Is the Pfizer-BioNtech Vaccine Variant-Resistant?
JUN 08, 2021
Is the Pfizer-BioNtech Vaccine Variant-Resistant?
Genetic variants of SARS-CoV-2 have emerged over the course of the pandemic, threatening public health efforts to limit ...
JUN 11, 2021
Cannabis Sciences
Can Cannabis Help Regulate Your Sleep Cycle?
JUN 11, 2021
Can Cannabis Help Regulate Your Sleep Cycle?
According to the Sleep Association, around 50-70 million adults in the US have a sleep disorder. Some claim that ca ...
JUN 17, 2021
Drug Discovery & Development
New COVID Drug Reduces Deaths in Patients with no Antibodies
JUN 17, 2021
New COVID Drug Reduces Deaths in Patients with no Antibodies
US drugmaker, Regeneron, in a partnership with Oxford University, has found that its new drug is capable of reducing COV ...
JUN 17, 2021
Drug Discovery & Development
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
JUN 17, 2021
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
The FDA recently approved a new drug known as Adulhelm, or aducanumab, to treat Alzheimer’s disease. The first new ...
Loading Comments...